Evidence map›Paper›PMID 40278335›Full record

ArticleJournal of personalized medicine2025

Genetic Predictors of Paxlovid Treatment Response: The Role of IFNAR2, OAS1, OAS3, and ACE2 in COVID-19 Clinical Course.

Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska, Pavlo Petakh, Valentyn Oksenych, Oleksandr Kamyshnyi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Observational
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mykhailo BuchynskyiDepartment of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0001-8735-0051
Iryna KamyshnaDepartment of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0002-4483-1856
Iryna HalabitskaDepartment of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, Voli Square, 1, 46001 Ternopil, Ukraine.ORCID 0000-0002-9028-7230
Pavlo PetakhDepartment of Biochemistry and Pharmacology, Uzhhorod National University, 88000 Uzhhorod, Ukraine.ORCID 0000-0002-0860-4445
Valentyn OksenychBroegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.ORCID 0000-0002-5088-3791
Oleksandr KamyshnyiDepartment of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine.ORCID 0000-0003-3141-4436

Funding

RECOOP Grant #36-CSMC Senior Scientists (RCSS)
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ACE2COVID-19IFNAR2nirmatrelvirOAS1OAS3Paxlovid

Identifiers

PMID40278335
PMCPMC12028499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.